Hyderabad, India / Florida, USA, 15th October, 2025: Zeus Hygia, a science-led nutraceutical ingredient manufacturer from India, announced a significant milestone in its international growth journey with the opening of its first US office in Florida. This strategic expansion strengthens the company’s global footprint and enhances its ability to serve key international markets.

Drawing from India’s centuries-old herbal wisdom rooted in Ayurveda, Zeus Hygia is at the forefront of transforming traditional knowledge into clinically validated nutraceuticals and botanical actives for the global nutraceutical and wellness industry.

As part of its global outreach, Zeus Hygia is also participating in leading nutraceutical and functional ingredient events across Southeast Asia, Japan, and Europe, thereby driving innovation-led partnerships in the global wellness industry.

Reflecting its commitment to excellence and science-backed innovation, Zeus Hygia’s flagship ingredients Grantria and Germin were honored with two prestigious awards at the 2025 NIE New Ingredient Awards. These recognitions showcase the company’s leadership in developing clinically validated, high-quality herbal extracts.

The global mandate is being led by Mr. Avileli Mouli Srikar, who brings extensive experience in the health and wellness sector, having spearheaded expansion projects across APAC, MENA, and ASEAN regions. Mouli has worked with some of the leading health and pharmaceutical companies, including AKAY Bioactives, Natural Remedies, Anthem Biosciences, and Sami-Sabinsa Group.

“Our vision has always been to make evidence-based natural wellness accessible to the world,” said Mr. Avileli Mouli Srikar, Head of Global Business, Zeus Hygia. “The US office launch is a significant step towards strengthening our presence in one of the most dynamic nutraceutical markets globally. We’re excited to build new collaborations and bring our innovations closer to partners and consumers worldwide.”

Further strengthening its innovation pipeline, Zeus Hygia is currently conducting clinical trials for a new portfolio of next-generation nutraceutical ingredients, with exciting developments on the horizon. It is poised to play a crucial role in shaping the future of the global nutraceutical industry.